Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese - PubMed (original) (raw)

doi: 10.1007/s10038-003-0120-5. Epub 2004 Feb 20.

Senji Shirasawa 1, Naofumi Ishikawa 3, Kunihiko Ito 3, Koichi Ito 3, Sumihisa Kubota 4, Kanji Kuma 4, Hajime Tamai 4, Takashi Akamizu 5, Hitomi Hiratani 5, Masao Tanaka 2, Takehiko Sasazuki 6

Affiliations

• PMID: 14986169
• DOI: 10.1007/s10038-003-0120-5

Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese

Koichi Furugaki et al. J Hum Genet. 2004.

Abstract

Autoimmune thyroid disease (AITD) is caused by an immune response to self-thyroid antigen. The cytotoxic T-lymphocyte antigen-4 ( CTLA4) gene, encoding a negative regulator of the T-lymphocyte immune response, had been reported to be associated and/or linked to AITD. Recently, AITD susceptibility in the Caucasians was mapped to the 6.1-kb 3'UTR of the CTLA4 gene, in which the three single-nucleotide polymorphisms (SNPs) CT60, JO31, and JO30 were strongly associated with AITD. In order to determine the association of the CTLA4 gene with AITD in the Japanese, case-control association analysis for the four SNPs of the CTLA4 gene using 380 AITD patients and 266 healthy controls was done. Among the SNPs examined, the SNP JO31 was most significantly associated with AITD in the Japanese, whereas the association of the JO30 with AITD was not observed. The frequency of the disease-susceptible G allele of the JO31 of the Japanese control was higher than that of the Caucasians (67.1% vs 50.2%); however, the G allele of the JO31 was associated with Graves' disease (GD) (67.1% vs 76.3%, P=0.0013) and AITD in the Japanese (67.1% vs 74.2%, P=0.0055). Furthermore, the G allele of the JO31 was associated with the increased risk for GD [ P=0.0051, odds ratio (OR)=1.7] and AITD ( P=0.016, OR=1.5) in a dominant model. These results suggested that the CTLA4 gene is involved in the susceptibility for GD and AITD in the Japanese.

PubMed Disclaimer

Similar articles

• Association of a CTLA-4 3' untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population.
  Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y. Ban Y, et al. Autoimmunity. 2005 Mar;38(2):151-3. doi: 10.1080/08916930500050319. Autoimmunity. 2005. PMID: 16040335
• Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
  Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Yin X, et al. Thyroid. 2008 Nov;18(11):1201-6. doi: 10.1089/thy.2008.0098. Thyroid. 2008. PMID: 18925838 Free PMC article.
• CTLA-4 and its role in autoimmune thyroid disease.
  Chistiakov DA, Turakulov RI. Chistiakov DA, et al. J Mol Endocrinol. 2003 Aug;31(1):21-36. doi: 10.1677/jme.0.0310021. J Mol Endocrinol. 2003. PMID: 12914522 Review.
• Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients.
  Akamizu T, Sale MM, Rich SS, Hiratani H, Noh JY, Kanamoto N, Saijo M, Miyamoto Y, Saito Y, Nakao K, Bowden DW. Akamizu T, et al. Thyroid. 2000 Oct;10(10):851-8. doi: 10.1089/thy.2000.10.851. Thyroid. 2000. PMID: 11081251
• The contribution of immune regulatory and thyroid specific genes to the etiology of Graves' and Hashimoto's diseases.
  Ban Y, Tomer Y. Ban Y, et al. Autoimmunity. 2003 Sep-Nov;36(6-7):367-79. doi: 10.1080/08916930310001603037. Autoimmunity. 2003. PMID: 14669944 Review.

Cited by

• Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto's Thyroiditis: How Far Is Our Understanding?
  Zeber-Lubecka N, Hennig EE. Zeber-Lubecka N, et al. Front Immunol. 2021 Feb 26;12:606620. doi: 10.3389/fimmu.2021.606620. eCollection 2021. Front Immunol. 2021. PMID: 33746952 Free PMC article. Review.
• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
  Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Chang LS, et al. Endocr Rev. 2019 Feb 1;40(1):17-65. doi: 10.1210/er.2018-00006. Endocr Rev. 2019. PMID: 30184160 Free PMC article. Review.
• Tremelimumab-Induced Graves Hyperthyroidism.
  Gan EH, Mitchell AL, Plummer R, Pearce S, Perros P. Gan EH, et al. Eur Thyroid J. 2017 Jul;6(3):167-170. doi: 10.1159/000464285. Epub 2017 Mar 14. Eur Thyroid J. 2017. PMID: 28785544 Free PMC article.
• Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common diseases.
  Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group; Matsuda K. Hirata M, et al. J Epidemiol. 2017 Mar;27(3S):S9-S21. doi: 10.1016/j.je.2016.12.003. Epub 2017 Feb 9. J Epidemiol. 2017. PMID: 28190657 Free PMC article.
• Pooled genome wide association detects association upstream of FCRL3 with Graves' disease.
  Khong JJ, Burdon KP, Lu Y, Laurie K, Leonardos L, Baird PN, Sahebjada S, Walsh JP, Gajdatsy A, Ebeling PR, Hamblin PS, Wong R, Forehan SP, Fourlanos S, Roberts AP, Doogue M, Selva D, Montgomery GW, Macgregor S, Craig JE. Khong JJ, et al. BMC Genomics. 2016 Nov 18;17(1):939. doi: 10.1186/s12864-016-3276-z. BMC Genomics. 2016. PMID: 27863461 Free PMC article.

References

1. 1. Hum Immunol. 1992 Nov;35(3):165-72 - PubMed
2. 1. J Clin Endocrinol Metab. 1997 Jan;82(1):143-6 - PubMed
3. 1. Nature. 1981 Aug 20;292(5825):768-70 - PubMed
4. 1. Am J Hum Genet. 1990 Feb;46(2):229-41 - PubMed
5. 1. Nature. 2003 May 29;423(6939):506-11 - PubMed

Publication types

MeSH terms

Substances